stockrowCharles River Laboratories International, Inc. (CRL) vs QIAGEN N.V. (QGEN)
- Charles River Laboratories International, Inc. CRL 328.72 +5.02%
- QIAGEN N.V. QGEN 50.47 −0.77%
Charles River Laboratories International, Inc. and QIAGEN N.V. are both Diagnostics & Research companies. Charles River Laboratories International, Inc. is the larger, with a market value of $14.9B against $10.5B — 1.4× the size. QIAGEN N.V. trades at the lower P/E: 26.1× against 300×. QIAGEN N.V. grew revenue faster over the last twelve months: 2.96% against −1.16%. QIAGEN N.V. has the higher net margin (19.5% vs 1.01%) and the higher return on invested capital (6.62% vs 1.81%). Across the 22 metrics below, QIAGEN N.V. leads on 19 and Charles River Laboratories International, Inc. on 3.
Valuation
Profitability
| Metric | CRL | QGEN | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 33.33% | 62.20% | 48.32% |
| Operating margin | 4.00% | 21.21% | (5.68%) |
| Net margin | 1.01% | 19.49% | (4.10%) |
| Free cash flow margin | 10.05% | 20.98% | 0.00% |
| Return on equity | 1.21% | 11.93% | 0.00% |
| Return on assets | 0.54% | 6.99% | (6.05%) |
| Return on invested capital | 1.81% | 6.62% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack